Tissue-specific dysregulation of cortisol regeneration by 11βHSD1 in obesity: Has it promised too much?

Diabetologia

Volumn 57, Issue 6, 2014, Pages 1100-1110

  Stomby, Andreas ^a   Andrew, Ruth ^b   Walker, Brian R ^b   Olsson, Tommy ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

11 Hydroxysteroid dehydrogenase type 1; 11 HSD1 inhibitors; Cortisol; Glucocorticoid metabolism; Obesity; Type 2 diabetes

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; 11BETA HYDROXYSTEROID DEHYDROGENASE 1 INHIBITOR; CORTICOTROPIN; CORTISONE; HYDROCORTISONE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXIDOREDUCTASE INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ABDOMINAL SUBCUTANEOUS FAT; ADIPOCYTE; AREA UNDER THE CURVE; BLOOD FLOWMETRY; BODY FAT; BODY FAT DISTRIBUTION; BODY MASS; CHOLESTEROL BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; ENZYME ACTIVITY; ENZYME INHIBITION; ESSENTIAL HYPERTENSION; FIRST PASS EFFECT; GLUCONEOGENESIS; GLYCOGENOLYSIS; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE URINE LEVEL; HYPERANDROGENISM; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; LIVER BIOPSY; LIVER CELL; LONG TERM CARE; LOW CARBOHYDRATE DIET; METABOLIC CLEARANCE RATE; METABOLIC DISORDER; NEGATIVE FEEDBACK; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUTRITIONAL STATUS; OBESITY; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REGENERATION; REVIEW; SKELETAL MUSCLE; SODIUM RETENTION; SPLANCHNIC BLOOD FLOW; SUBCUTANEOUS FAT; SYSTOLIC BLOOD PRESSURE; TISSUE SPECIFICITY; UPREGULATION; WAIST CIRCUMFERENCE; WAIST HIP RATIO; ENZYMOLOGY; GENETICS; METABOLISM;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; HYDROCORTISONE; OBESITY;

EID: 84901228517     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-014-3228-6     Document Type: Review

References (100)

1. Chanson P, Salenave S (2010) Metabolic syndrome in Cushing's syndrome. Neuroendocrinology 92(Suppl 1):96-101
2. Wei L, MacDonald TM, Walker BR (2004) Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 141:764-770
3. Andrew R, Phillips DI, Walker BR (1998) Obesity and gender influence cortisol secretion and metabolism in man. J Clin Endocrinol Metab 83:1806-1809
4. Stimson RH, Andrew R, McAvoy NC, Tripathi D, Hayes PC, Walker BR (2011) Increased whole-body and sustained liver cortisol regeneration by 11β-hydroxysteroid dehydrogenase type 1 in obese men with type 2 diabetes provides a target for enzyme inhibition. Diabetes 60:720-725
5. Ljung T, Andersson B, Bengtsson BA, Bjorntorp P, Marin P (1996) Inhibition of cortisol secretion by dexamethasone in relation to body fat distribution: a dose-response study. Obes Res 4:277-282
6. Glass AR, Burman KD, Dahms WT, Boehm TM (1981) Endocrine function in human obesity. Metabolism 30:89-104
7. Hautanen A, Adlercreutz H (1993) Altered adrenocorticotropin and cortisol secretion in abdominal obesity: implications for the insulin resistance syndrome. J Intern Med 234:461-469
8. Kumari M, Chandola T, Brunner E, Kivimaki M (2010) A nonlinear relationship of generalized and central obesity with diurnal cortisol secretion in the Whitehall II study. J Clin Endocrinol Metab 95:4415-4423
9. Strain GW, Zumoff B, Strain JJ, Levin J, Fukushima DK (1980) Cortisol production in obesity. Metabolism 29:980-985
10. Lottenberg SA, Giannella-Neto D, Derendorf H et al (1998) Effect of fat distribution on the pharmacokinetics of cortisol in obesity. Int J Clin Pharmacol Ther 36:501-505
11. Stimson RH, Andersson J, Andrew R et al (2009) Cortisol release from adipose tissue by 11β-hydroxysteroid dehydrogenase type 1 in humans. Diabetes 58:46-53
12. Agarwal AK, Monder C, Eckstein B, White PC (1989) Cloning and expression of rat cDNA encoding corticosteroid 11β-dehydrogenase. J Biol Chem 264:18939-18943
13. Albiston AL, Obeyesekere VR, Smith RE, Krozowski ZS (1994) Cloning and tissue distribution of the human 11β-hydroxysteroid dehydrogenase type 2 enzyme. Mol Cell Endocrinol 105:R11-R17
14. Lakshmi V, Monder C (1988) Purification and characterization of the corticosteroid 11β-dehydrogenase component of the rat liver 11β-hydroxysteroid dehydrogenase complex. Endocrinology 123:2390-2398
15. Jamieson PM, Chapman KE, Edwards CR, Seckl JR (1995) 11β- hydroxysteroid dehydrogenase is an exclusive 11β- reductase in primary cultures of rat hepatocytes: effect of physicochemical and hormonal manipulations. Endocrinology 136:4754-4761
16. Bujalska IJ, Kumar S, Stewart PM (1997) Does central obesity reflect "Cushing's disease of the omentum"? Lancet 349:1210-1213
17. Sandeep TC, Yau JL, MacLullich AM et al (2004) 11β-hydroxysteroid dehydrogenase inhibition improves cognitive function in healthy elderly men and type 2 diabetics. Proc Natl Acad Sci U S A 101:6734-6739
18. Kipari T, Hadoke PW, Iqbal J et al (2013) 11β-hydroxysteroid dehydrogenase type 1 deficiency in bone marrow-derived cells reduces atherosclerosis. FASEB J 27:1519-1531
19. Jang C, Obeyesekere VR, Dilley RJ, Alford FP, Inder WJ (2006) 11β hydroxysteroid dehydrogenase type 1 is expressed and is biologically active in human skeletal muscle. Clin Endocrinol (Oxf) 65:800-805
20. Stewart PM, Corrie JE, Shackleton CH, Edwards CR (1988) Syndrome of apparent mineralocorticoid excess. A defect in the cortisol-cortisone shuttle. J Clin Invest 82:340-349
21. Seckl JR, Walker BR (2001) Minireview: 11β-hydroxysteroid dehydrogenase type 1 - a tissue-specific amplifier of glucocorticoid action. Endocrinology 142:1371-1376
22. Walker BR, Connacher AA, Lindsay RM, Webb DJ, Edwards CR (1995) Carbenoxolone increases hepatic insulin sensitivity in man: a novel role for 11-oxosteroid reductase in enhancing glucocorticoid receptor activation. J Clin Endocrinol Metab 80:3155-3159
23. Kotelevtsev Y, Holmes MC, Burchell A et al (1997) 11β-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc Natl Acad Sci U S A 94:14924-14929
24. Stewart PM, Boulton A, Kumar S, Clark PM, Shackleton CH (1999) Cortisol metabolism in human obesity: impaired cortisone→cortisol conversion in subjects with central adiposity. J Clin Endocrinol Metab 84:1022-1027
25. Livingstone DE, Jones GC, Smith K et al (2000) Understanding the role of glucocorticoids in obesity: tissue-specific alterations of corticosterone metabolism in obese Zucker rats. Endocrinology 141:560-563
26. Rask E, Olsson T, Soderberg S et al (2001) Tissue-specific dysregulation of cortisol metabolism in human obesity. J Clin Endocrinol Metab 86:1418-1421
27. Rask E, Walker BR, Soderberg S et al (2002) Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11β-hydroxysteroid dehydrogenase type 1 activity. J Clin Endocrinol Metab 87:3330-3336
28. Best R, Walker BR (1997) Additional value of measurement of urinary cortisone and unconjugated cortisol metabolites in assessing the activity of 11β-hydroxysteroid dehydrogenase in vivo. Clin Endocrinol (Oxf) 47:231-236
29. Fraser R, Ingram MC, Anderson NH, Morrison C, Davies E, Connell JM (1999) Cortisol effects on body mass, blood pressure, and cholesterol in the general population. Hypertension 33:1364-1368
30. Westerbacka J, Yki-Jarvinen H, Vehkavaara S et al (2003) Body fat distribution and cortisol metabolism in healthy men: enhanced 5β-reductase and lower cortisol/cortisone metabolite ratios in men with fatty liver. J Clin Endocrinol Metab 88:4924-4931
31. Tomlinson JW, Finney J, Gay C, Hughes BA, Hughes SV, Stewart PM (2008) Impaired glucose tolerance and insulin resistance are associated with increased adipose 11β-hydroxysteroid dehydrogenase type 1 expression and elevated hepatic 5α-reductase activity. Diabetes 57:2652-2660
32. Walker BR, Stewart PM, Shackleton CH, Padfield PL, Edwards CR (1993) Deficient inactivation of cortisol by 11β-hydroxysteroid dehydrogenase in essential hypertension. Clin Endocrinol (Oxf) 39:221-227
33. Veilleux A, Rheaume C, Daris M, Luu-The V, Tchernof A (2009) Omental adipose tissue type 1 11β-hydroxysteroid dehydrogenase oxoreductase activity, body fat distribution, and metabolic alterations in women. J Clin Endocrinol Metab 94:3550-3557
34. Torrecilla E, Fernandez-Vazquez G, Vicent D et al (2012) Liver upregulation of genes involved in cortisol production and action is associated with metabolic syndrome in morbidly obese patients. Obes Surg 22:478-486
35. Desbriere R, Vuaroqueaux V, Achard V et al (2006) 11β-hydroxysteroid dehydrogenase type 1 mRNA is increased in both visceral and subcutaneous adipose tissue of obese patients. Obesity (Silver Spring) 14:794-798
36. Paulmyer-Lacroix O, Boullu S, Oliver C, Alessi MC, Grino M (2002) Expression of the mRNA coding for 11β-hydroxysteroid dehydrogenase type 1 in adipose tissue from obese patients: an in situ hybridization study. J Clin Endocrinol Metab 87:2701-2705
37. Lindsay RS, Wake DJ, Nair S et al (2003) Subcutaneous adipose 11β-hydroxysteroid dehydrogenase type 1 activity and messenger ribonucleic acid levels are associated with adiposity and insulinemia in Pima Indians and Caucasians. J Clin Endocrinol Metab 88:2738-2744
38. Lee MJ, Fried SK, Mundt SS et al (2008) Depot-specific regulation of the conversion of cortisone to cortisol in human adipose tissue. Obesity (Silver Spring) 16:1178-1185
39. Paulsen SK, Pedersen SB, Fisker S, Richelsen B (2007) 11β-HSD type 1 expression in human adipose tissue: impact of gender, obesity, and fat localization. Obesity (Silver Spring) 15:1954-1960
40. Sandeep TC, Andrew R, Homer NZ, Andrews RC, Smith K, Walker BR (2005) Increased in vivo regeneration of cortisol in adipose tissue in human obesity and effects of the 11β-hydroxysteroid dehydrogenase type 1 inhibitor carbenoxolone. Diabetes 54:872-879
41. Tomlinson JW, Sinha B, Bujalska I, Hewison M, Stewart PM (2002) Expression of 11β-hydroxysteroid dehydrogenase type 1 in adipose tissue is not increased in human obesity. J Clin Endocrinol Metab 87:5630-5635
42. Goedecke JH, Wake DJ, Levitt NS et al (2006) Glucocorticoid metabolism within superficial subcutaneous rather than visceral adipose tissue is associated with features of the metabolic syndrome in South African women. Clin Endocrinol (Oxf) 65:81-87
43. Michailidou Z, Jensen MD, Dumesic DA et al (2007) Omental 11β-hydroxysteroid dehydrogenase 1 correlates with fat cell size independently of obesity. Obesity (Silver Spring) 15:1155-1163
44. Andrew R, Smith K, Jones GC, Walker BR (2002) Distinguishing the activities of 11β-hydroxysteroid dehydrogenases in vivo using isotopically labeled cortisol. J Clin Endocrinol Metab 87:277-285
45. Andrew R, Westerbacka J, Wahren J, Yki-Jarvinen H, Walker BR (2005) The contribution of visceral adipose tissue to splanchnic cortisol production in healthy humans. Diabetes 54:1364-1370
46. Basu R, Singh RJ, Basu A et al (2005) Obesity and type 2 diabetes do not alter splanchnic cortisol production in humans. J Clin Endocrinol Metab 90:3919-3926
47. Basu R, Basu A, Grudzien M et al (2009) Liver is the site of splanchnic cortisol production in obese nondiabetic humans. Diabetes 58:39-45
48. Hughes KA, Manolopoulos KN, Iqbal J et al (2012) Recycling between cortisol and cortisone in human splanchnic, subcutaneous adipose, and skeletal muscle tissues in vivo. Diabetes 61:1357-1364
49. Baudrand R, Carvajal CA, Riquelme A et al (2010) Overexpression of 11β-hydroxysteroid dehydrogenase type 1 in hepatic and visceral adipose tissue is associated with metabolic disorders in morbidly obese patients. Obes Surg 20:77-83
50. Andrews RC, Herlihy O, Livingstone DE, Andrew R, Walker BR (2002) Abnormal cortisol metabolism and tissue sensitivity to cortisol in patients with glucose intolerance. J Clin Endocrinol Metab 87:5587-5593
51. Whorwood CB, Donovan SJ, Flanagan D, Phillips DI, Byrne CD (2002) Increased glucocorticoid receptor expression in human skeletal muscle cells may contribute to the pathogenesis of the metabolic syndrome. Diabetes 51:1066-1075
52. Abdallah BM, Beck-Nielsen H, Gaster M (2005) Increased expression of 11β-hydroxysteroid dehydrogenase type 1 in type 2 diabetic myotubes. Eur J Clin Invest 35:627-634
53. Masuzaki H, Paterson J, Shinyama H et al (2001) A transgenic model of visceral obesity and the metabolic syndrome. Science 294:2166-2170
54. Morton NM, Holmes MC, Fievet C et al (2001) Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11β-hydroxysteroid dehydrogenase type 1 null mice. J Biol Chem 276:41293-41300
55. Michailidou Z, Turban S, Miller E et al (2012) Increased angiogenesis protects against adipose hypoxia and fibrosis in metabolic disease-resistant 11β-hydroxysteroid dehydrogenase type 1 (HSD1)-deficient mice. J Biol Chem 287:4188-4197
56. Paterson JM, Morton NM, Fievet C et al (2004) Metabolic syndrome without obesity: hepatic overexpression of 11β-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc Natl Acad Sci U S A 101:7088-7093
57. Lavery GG, Zielinska AE, Gathercole LL et al (2012) Lack of significant metabolic abnormalities in mice with liver-specific disruption of 11β-hydroxysteroid dehydrogenase type 1. Endocrinology 153:3236-3248
58. Morgan SA, Sherlock M, Gathercole LL et al (2009) 11β-hydroxysteroid dehydrogenase type 1 regulates glucocorticoid-induced insulin resistance in skeletal muscle. Diabetes 58:2506-2515
59. Tomlinson JW, Walker EA, Bujalska IJ et al (2004) 11β-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr Rev 25:831-866
60. Liu YJ, Nakagawa Y, Nasuda K, Saegusa H, Igarashi Y (1996) Effect of growth hormone, insulin and dexamethasone on 11β-hydroxysteroid dehydrogenase activity on a primary culture of rat hepatocytes. Life Sci 59:227-234
61. Napolitano A, Voice MW, Edwards CR, Seckl JR, Chapman KE (1998) 11β-hydroxysteroid dehydrogenase 1 in adipocytes: expression is differentiation-dependent and hormonally regulated. J Steroid Biochem Mol Biol 64:251-260
62. Wake DJ, Homer NZ, Andrew R, Walker BR (2006) Acute in vivo regulation of 11β-hydroxysteroid dehydrogenase type 1 activity by insulin and intralipid infusions in humans. J Clin Endocrinol Metab 91:4682-4688
63. Stimson RH, Mohd-Shukri NA, Bolton JL, Andrew R, Reynolds RM, Walker BR (2014) The post-prandial rise in plasma cortisol in men is mediated by macronutrient-specific stimulation of adrenal and extra-adrenal cortisol production. J Clin Endocrinol Metab 160-168
64. Stimson RH, Johnstone AM, Homer NZ et al (2007) Dietary macronutrient content alters cortisol metabolism independently of body weight changes in obese men. J Clin Endocrinol Metab 92:4480-4484
65. Poulsen L, Siersbaek M, Mandrup S (2012) PPARs: fatty acid sensors controlling metabolism. Semin Cell Dev Biol 23:631-639
66. Mai K, Andres J, Bobbert T et al (2007) Rosiglitazone decreases 11β-hydroxysteroid dehydrogenase type 1 in subcutaneous adipose tissue. Clin Endocrinol (Oxf) 67:419-425
67. Hermanowski-Vosatka A, Gerhold D, Mundt SS et al (2000) PPARα agonists reduce 11β-hydroxysteroid dehydrogenase type 1 in the liver. Biochem Biophys Res Commun 279:330-336
68. Wake DJ, Stimson RH, Tan GD et al (2007) Effects of peroxisome proliferator-activated receptor-α and -γ agonists on 11β-hydroxysteroid dehydrogenase type 1 in subcutaneous adipose tissue in men. J Clin Endocrinol Metab 92:1848-1856
69. Bogacka I, Xie H, Bray GA, Smith SR (2004) The effect of pioglitazone on peroxisome proliferator-activated receptor-γ target genes related to lipid storage in vivo. Diabetes Care 27:1660-1667
70. Moore JS, Monson JP, Kaltsas G et al (1999) Modulation of 11β-hydroxysteroid dehydrogenase isozymes by growth hormone and insulin-like growth factor: in vivo and in vitro studies. J Clin Endocrinol Metab 84:4172-4177
71. Giavoli C, Libe R, Corbetta S et al (2004) Effect of recombinant human growth hormone (GH) replacement on the hypothalamic-pituitary-adrenal axis in adult GH-deficient patients. J Clin Endocrinol Metab 89:5397-5401
72. Gelding SV, Taylor NF, Wood PJ et al (1998) The effect of growth hormone replacement therapy on cortisol-cortisone interconversion in hypopituitary adults: evidence for growth hormone modulation of extrarenal 11β-hydroxysteroid dehydrogenase activity. Clin Endocrinol (Oxf) 48:153-162
73. Sigurjonsdottir HA, Andrew R, Stimson RH, Johannsson G, Walker BR (2009) Lack of regulation of 11β-hydroxysteroid dehydrogenase type 1 during short-term manipulation of GH in patients with hypopituitarism. Eur J Endocrinol 161:375-380
74. Andersson T, Soderstrom I, Simonyte K, Olsson T (2010) Estrogen reduces 11β-hydroxysteroid dehydrogenase type 1 in liver and visceral, but not subcutaneous, adipose tissue in rats. Obesity (Silver Spring) 18:470-475
75. McInnes KJ, Andersson TC, Simonyte K et al (2012) Association of 11β-hydroxysteroid dehydrogenase type I expression and activity with estrogen receptor β in adipose tissue from postmenopausal women. Menopause 19:1347-1352
76. Andersson T, Simonyte K, Andrew R et al (2009) Tissue-specific increases in 11β-hydroxysteroid dehydrogenase type 1 in normal weight postmenopausal women. PLoS ONE 4:e8475
77. Tomlinson JW, Moore J, Cooper MS et al (2001) Regulation of expression of 11β-hydroxysteroid dehydrogenase type 1 in adipose tissue: tissue-specific induction by cytokines. Endocrinology 142:1982-1989
78. Koska J, Ortega E, Bunt JC et al (2009) The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomised double-blind placebo-controlled study. Diabetologia 52:385-393
79. Nixon M, Wake DJ, Livingstone DE et al (2012) Salicylate downregulates 11β-HSD1 expression in adipose tissue in obese mice and in humans, mediating insulin sensitization. Diabetes 61:790-796
80. Wang YJ, Huang SL, Feng Y, Ning MM, Leng Y (2012) Emodin, an 11β-hydroxysteroid dehydrogenase type 1 inhibitor, regulates adipocyte function in vitro and exerts anti-diabetic effect in ob/ob mice. Acta Pharmacol Sin 33:1195-1203
81. Alberts P, Engblom L, Edling N et al (2002) Selective inhibition of 11β-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice. Diabetologia 45:1528-1532
82. Alberts P, Nilsson C, Selen G et al (2003) Selective inhibition of 11β-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains. Endocrinology 144:4755-4762
83. Harno E, Cottrell EC, Yu A et al (2013) 11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors still improve metabolic phenotype in male 11β-HSD1 knockout mice suggesting off-target mechanisms. Endocrinology 154:4580-4593
84. Edgerton DS, Basu R, Ramnanan CJ et al (2010) Effect of 11β-hydroxysteroid dehydrogenase-1 inhibition on hepatic glucose metabolism in the conscious dog. Am J Physiol Endocrinol Metab 298:E1019-E1026
85. Winnick JJ, Ramnanan CJ, Saraswathi V et al (2013) Effects of 11β-hydroxysteroid dehydrogenase-1 inhibition on hepatic glycogenolysis and gluconeogenesis. Am J Physiol Endocrinol Metab 304:E747-E756
86. Andrews RC, Rooyackers O, Walker BR (2003) Effects of the 11β-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes. J Clin Endocrinol Metab 88:285-291
87. Livingstone DE, Walker BR (2003) Is 11β-hydroxysteroid dehydrogenase type 1 a therapeutic target? Effects of carbenoxolone in lean and obese Zucker rats. J Pharmacol Exp Ther 305:167-172
88. Shah S, Hermanowski-Vosatka A, Gibson K et al (2011) Efficacy and safety of the selective 11β-HSD-1 inhibitors MK-0736 and MK-0916 in overweight and obese patients with hypertension. J Am Soc Hypertens 5:166-176
89. Feig PU, Shah S, Hermanowski-Vosatka A et al (2011) Effects of an 11β-hydroxysteroid dehydrogenase type 1 inhibitor, MK-0916, in patients with type 2 diabetes mellitus and metabolic syndrome. Diabetes Obes Metab 13:498-504
90. Rosenstock J, Banarer S, Fonseca VA et al (2010) The 11-β- hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy. Diabetes Care 33:1516-1522
91. Marek GJ, Katz DA, Meier A et al (2014) Efficacy and safety evaluation of HSD-1 inhibitor ABT-384 in Alzheimer's disease. Alzheimers Dement. doi: 10.1016/j.jalz.2013.09.010
92. Harris HJ, Kotelevtsev Y, Mullins JJ, Seckl JR, Holmes MC (2001) Intracellular regeneration of glucocorticoids by 11β-hydroxysteroid dehydrogenase (11β-HSD)-1 plays a key role in regulation of the hypothalamic-pituitary-adrenal axis: analysis of 11β-HSD-1-deficient mice. Endocrinology 142:114-120
93. Draper N, Walker EA, Bujalska IJ et al (2003) Mutations in the genes encoding 11β-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase interact to cause cortisone reductase deficiency. Nat Genet 34:434-439
94. Berthiaume M, Laplante M, Festuccia WT, Berger JP, Thieringer R, Deshaies Y (2010) Preliminary report: pharmacologic 11β-hydroxysteroid dehydrogenase type 1 inhibition increases hepatic fat oxidation in vivo and expression of related genes in rats fed an obesogenic diet. Metabolism 59:114-117
95. - mice. PLoS ONE 8:e53192
96. Sooy K, Webster SP, Noble J et al (2010) Partial deficiency or short-term inhibition of 11β-hydroxysteroid dehydrogenase type 1 improves cognitive function in aging mice. J Neurosci 30:13867-13872
97. McSweeney SJ, Hadoke PW, Kozak AM et al (2010) Improved heart function follows enhanced inflammatory cell recruitment and angiogenesis in 11βHSD1-deficient mice post-MI. Cardiovasc Res 88:159-167
98. Small GR, Hadoke PW, Sharif I et al (2005) Preventing local regeneration of glucocorticoids by 11β-hydroxysteroid dehydrogenase type 1 enhances angiogenesis. Proc Natl Acad Sci U S A 102:12165-12170
99. Youm JK, Park K, Uchida Y et al (2013) Local blockade of glucocorticoid activation reverses stress- and glucocorticoid-induced delays in cutaneous wound healing. Wound Repair Regen 21:715-722
100. Tiganescu A, Tahrani AA, Morgan SA et al (2013) 11β-Hydroxysteroid dehydrogenase blockade prevents age-induced skin structure and function defects. J Clin Invest 123:3051-3060